Twist Bioscience (NASDAQ:TWST) Now Covered by Analysts at Guggenheim

Guggenheim initiated coverage on shares of Twist Bioscience (NASDAQ:TWSTFree Report) in a report issued on Tuesday morning, MarketBeat.com reports. The firm issued a buy rating and a $53.00 price target on the stock.

Other equities analysts have also issued research reports about the stock. Barclays boosted their price objective on shares of Twist Bioscience from $40.00 to $45.00 and gave the company an overweight rating in a research report on Friday, May 3rd. Scotiabank raised their price objective on Twist Bioscience from $43.00 to $48.00 and gave the stock a sector outperform rating in a report on Monday, May 6th. Robert W. Baird lifted their price objective on Twist Bioscience from $39.00 to $40.00 and gave the company an outperform rating in a research report on Friday, May 3rd. Finally, Evercore ISI increased their target price on Twist Bioscience from $46.00 to $50.00 and gave the stock an outperform rating in a research report on Friday, May 3rd. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of Buy and an average target price of $44.00.

Check Out Our Latest Analysis on TWST

Twist Bioscience Price Performance

NASDAQ TWST opened at $53.00 on Tuesday. The business has a 50 day moving average price of $37.62 and a 200 day moving average price of $35.39. The company has a market capitalization of $3.09 billion, a P/E ratio of -15.72 and a beta of 1.78. Twist Bioscience has a 1-year low of $14.42 and a 1-year high of $54.13.

Twist Bioscience (NASDAQ:TWSTGet Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.05. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. The company had revenue of $75.30 million for the quarter, compared to the consensus estimate of $70.70 million. During the same quarter in the prior year, the firm earned ($1.06) earnings per share. The company’s revenue for the quarter was up 25.1% compared to the same quarter last year. On average, research analysts expect that Twist Bioscience will post -3.08 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Paula Green sold 910 shares of the stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $37.13, for a total transaction of $33,788.30. Following the sale, the senior vice president now owns 91,511 shares in the company, valued at $3,397,803.43. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Twist Bioscience news, SVP Paula Green sold 910 shares of the stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $37.13, for a total value of $33,788.30. Following the sale, the senior vice president now directly owns 91,511 shares of the company’s stock, valued at $3,397,803.43. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider William Banyai sold 798 shares of the stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $37.13, for a total transaction of $29,629.74. Following the completion of the sale, the insider now directly owns 345,188 shares in the company, valued at approximately $12,816,830.44. The disclosure for this sale can be found here. Insiders sold a total of 14,875 shares of company stock valued at $519,432 over the last 90 days. 3.92% of the stock is owned by company insiders.

Hedge Funds Weigh In On Twist Bioscience

Institutional investors and hedge funds have recently bought and sold shares of the stock. Federated Hermes Inc. acquired a new stake in Twist Bioscience in the third quarter worth approximately $29,000. EdgeRock Capital LLC bought a new position in Twist Bioscience during the fourth quarter valued at about $30,000. Headlands Technologies LLC acquired a new position in Twist Bioscience during the first quarter worth about $124,000. International Assets Investment Management LLC raised its position in Twist Bioscience by 3,519.8% in the fourth quarter. International Assets Investment Management LLC now owns 4,018 shares of the company’s stock worth $148,000 after acquiring an additional 3,907 shares in the last quarter. Finally, Brown Advisory Inc. acquired a new stake in Twist Bioscience in the 4th quarter valued at about $225,000.

Twist Bioscience Company Profile

(Get Free Report)

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Featured Articles

Analyst Recommendations for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.